

## Preferred Drug List Announcement

MO HealthNet Division (MHD) is continuing the state-specific Preferred Drug List (PDL) evaluation process. Drug/Drug classes for review for the upcoming quarter are identified at each of the quarterly meetings of the Drug Prior Authorization Committee and also posted on the Division's web page at <http://dss.mo.gov/mhd/cs/pharmacy/pdf/pdla.pdf> shortly following each meeting.

MO HealthNet Division's clinical team will conduct the clinical reviews of the drug products under evaluation each quarter. For preferred status consideration for your product, a more detailed review request should be presented to MHD. All clinical information for consideration should be forwarded to Joshua Moore at [Joshua.S.Moore@dss.mo.gov](mailto:Joshua.S.Moore@dss.mo.gov) or call (573) 751-6961. These submissions should generally follow the AMCP guideline format. Financial evaluations for these therapeutic class reviews are conducted by Conduent State HealthCare, LLC. Companies wishing to discuss opportunities for supplemental rebates should contact Conduent State HealthCare, LLC at (804) 965-8117.

If you have any questions concerning the PDL submission process, or the policy surrounding the process, feel free to contact the pharmacy program at [MHD.ClinicalServices@dss.mo.gov](mailto:MHD.ClinicalServices@dss.mo.gov) or (573) 751-6963. If a public presentation is desired, please contact **Carmen Burton** at [Carmen.M.Burton@dss.mo.gov](mailto:Carmen.M.Burton@dss.mo.gov) or call (573) 751-6961. The Drug PA Committee will convene at **10:00 a.m. on Thursday, December 16, 2021.**

### Drug Therapeutic Class Name

- Alzheimer's Agents, Cholinesterase Inhibitors, NMDA Receptor Antagonists, and Combinations
- Antiandrogenic Agents
- Anticonvulsants, Dravet Syndrome
- Antiemetics, 5-HT3 and NK1 Injectable
- Antiemetics, 5-HT3, NK1 & Other Select Non-Injectable
- Antiemetics, THC Derivatives
- Anti-Migraine Agents, Alternative Oral
- Anti-Migraine Agents, Serotonin (5-HT1) Receptor Agonists
- Anti-Parkinsonism, MAO-B Inhibitors
- Anti-Parkinsonism, Non-Ergot Dopamine Agonists
- Antiretrovirals, Treatment Products
- Atypical Antipsychotics, Depot (Reference List)
- Atypical Antipsychotics, Oral and Transdermal (Reference List)
- Calcitonin Gene-Related Peptide (CGRP) Receptor Inhibitors
- Cyclin-Dependent Kinase (CDK) 4/6 Inhibitors
- Fibromyalgia Agents
- GI Motility Agents
- Glucagon Agents
- Hereditary Angioedema Agents
- Neuropathic Pain Agents
- NSAIDs
- Opioid Emergency Reversal Agents
- Opioid Dependence Agents
- Opioids, Long Acting
- Sedative Hypnotics
- Skeletal Muscle Relaxants
- Somatostatin Analogs
- Tramadol-Like Agents
- Vesicular Monoamine Transporter 2 (VMAT2) Inhibitors